Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan

PHASE2CompletedINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Alogliptin

Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks

DRUG

Alogliptin

Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Alogliptin

Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Alogliptin

Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks

DRUG

Voglibose

Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.

DRUG

Placebo

Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.

Trial Locations (1)

701-0192

Okayama

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY